Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Arlocabtagene Autoleucel · BMS-986393, CC-95266

Cell therapy (CAR-T) · Kills target cells, directed at GPRC5D · developed by BRISTOL MYERS SQUIBB

Phase 3 Most advanced trial
BMY Developer
1 Registered trials

What is Arlocabtagene Autoleucel?

Arlocabtagene autoleucel is an autologous T-lymphocyte cell therapy engineered to express a chimeric antigen receptor specific for GPRC5D, a protein overexpressed in certain malignancies such as multiple myeloma. The engineered cells recognize GPRC5D-expressing tumor cells and induce selective toxicity against them. It is being studied in relapsed or refractory multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BMS-986393, CC-95266, Arlo-cel
Drug type
Cell therapy (CAR-T)
Targets
GPRC5D (antigen)
Mechanism
Kills target cells, directed at GPRC5D
Therapy area
Oncology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
WQ79GLJ8VP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06615479 Phase 3 Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed or Refractory Multiple Myeloma (RRMM)

Other drugs acting on GPRC5D

More from BRISTOL MYERS SQUIBB

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Arlocabtagene Autoleucel

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.